|
🐬
|
Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial
E. Chung,
M. Packer,
K. Lo,
A. Fasanmade,
J. Willerson
|
10 |
2003 |
10
🐬
|
|
🐜
|
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial.
7 auth.
E. St.clair,
C. Wagner,
A. Fasanmade,
Benjamin Wang,
T. Schaible,
A. Kavanaugh,
...
E. Keystone
|
8 |
2002 |
8
🐜
|
|
🐜
|
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.
39 auth.
N. Ruperto,
D. Lovell,
R. Cuttica,
N. Wilkinson,
P. Woo,
G. Espada,
C. Wouters,
E. Silverman,
Z. Balogh,
M. Henrickson,
M. Apaz,
E. Baildam,
A. Fasth,
V. Gerloni,
P. Lahdenne,
...
A. Prieur,
A. Ravelli,
R. Saurenmann,
M. Gamir,
N. Wulffraat,
L. Maródi,
R. Petty,
R. Joos,
F. Zulian,
D. McCurdy,
B. Myones,
K. Nagy,
P. Reuman,
I. Szer,
S. Travers,
A. Beutler,
G. Keenan,
Jason Clark,
S. Visvanathan,
A. Fasanmade,
A. Raychaudhuri,
A. Mendelsohn,
A. Martini,
E. Giannini
|
8 |
2007 |
8
🐜
|
|
🦁
|
Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
A. Fasanmade,
O. Adedokun,
M. Blank,
Honghui Zhou,
H. Davis
|
8 |
2011 |
8
🦁
|
|
🐜
|
Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
11 auth.
M. Rosario,
N. Dirks,
M. Gastonguay,
A. Fasanmade,
Timothy Wyant,
A. Parikh,
...
W. Sandborn,
B. Feagan,
W. Reinisch,
W. Reinisch,
I. Fox
|
7 |
2015 |
7
🐜
|
|
🦁
|
PHARMACOKINETICS AND DISPOSITION Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
8 auth.
A. Fasanmade,
O. Adedokun,
J. Ford,
Danika Hernandez,
J. Johanns,
Chuanpu Hu,
...
Hugh M. Davis,
Honghui Zhou
|
7 |
2009 |
7
🦁
|
|
🐜
|
Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris.
9 auth.
A. Gottlieb,
S. Masud,
R. Ramamurthi,
Ahsan A. Abdulghani,
P. Romano,
U. Chaudhari,
...
L. T. Dooley,
A. Fasanmade,
C. Wagner
|
7 |
2003 |
7
🐜
|
|
🐜
|
2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatment extension
21 auth.
N. Ruperto,
D. Lovell,
R. Cuttica,
P. Woo,
G. Espada,
C. Wouters,
E. Silverman,
Z. Balogh,
M. Henrickson,
J. Davidson,
...
I. Foeldvari,
L. Imundo,
G. Simonini,
J. Oppermann,
YK Shen,
S. Visvanathan,
A. Fasanmade,
A. Mendelsohn,
A. Martini,
E. Giannini,
for the Paediatric Rheumatology International Trials O Group
|
6 |
2008 |
6
🐜
|
|
🐜
|
Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis
8 auth.
Zhenhua Xu,
K. Seitz,
A. Fasanmade,
J. Ford,
P. Williamson,
Weichun Xu,
...
H. Davis,
Honghui Zhou
|
6 |
2008 |
6
🐜
|
|
🐜
|
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
12 auth.
B. Brockstein,
D. Haraf,
K. Stenson,
A. Fasanmade,
R. Stupp,
B. Glisson,
...
S. M. Lippman,
M. Ratain,
Laura Sulzen,
Amy Klepsch,
R. Weichselbaum,
E. Vokes
|
6 |
1998 |
6
🐜
|
|
🦁
|
Determination of chlorpromazine and its sulphoxide in pharmaceutical dosage forms by third-order derivative ultraviolet spectroscopy.
A. Fasanmade,
A. Fell
|
6 |
1985 |
6
🦁
|
